Literature DB >> 20212337

Antimicrobial resistance in pathogens causing nosocomial infections in surgery and intensive care units of two hospitals in Antananarivo, Madagascar.

Frédérique Randrianirina1, Laetitia Vaillant, Charles Emile Ramarokoto, Armand Rakotoarijaona, Mamy Lalatiana Andriamanarivo, Henri Claude Razafimahandry, Jules Randrianomenjanahary, Jean Roger Raveloson, Elisoa Ratsima Hariniana, Jean-François Carod, Antoine Talarmin, Vincent Richard.   

Abstract

BACKGROUND: In developing countries, knowledge of antimicrobial resistance patterns is essential to define empirical therapy.
METHODOLOGY: All the surgery and intensive care wards of two hospitals in Antananarivo were included to study the antimicrobial susceptibility of the pathogenic bacteria causing nosocomial infections. A repeated cross-sectional survey was conducted between September 2006 and March 2008, one day per week. Isolates were identified using classical methods, and resistance to antibiotics was assessed according to the recommendations of the Antibiogram Committee of the French Microbiology Society.
RESULTS: Clinical specimens from 706 from 651 patients were collected. Of the 533 bacterial pathogens, 46.7% were Enterobacteriaceae, 19.3% were Staphylococcus aureus, and 19.1% were pathogens from the hospital environment (Pseudomonas aeruginosa and Acinetobacter baumannii).Frequencies of resistance were high, particularly in Enterobacteriaceae; however, the rate of Staphylococcus aureus isolates resistant to oxacillin (13.6 %) was moderate and all these isolates were susceptible to glycopeptids. The percentages of isolates susceptible to ceftazidim were 81.8% for E. coli, 60.9% for Klebsiella, and 52.5% for Enterobacter spp. Resistance to third-generation cephalosporins was due to extended spectrum betalactamases (ESBL). Multivariate analysis showed that diabetes (adjusted OR: 3.9) and use of an invasive procedures (adjusted OR: 3.5) were independent risk factors for resistance to third-generation cephalosporins.
CONCLUSION: A nationwide surveillance programme is needed to monitor the microbial trends and antimicrobial resistance in Madagascar.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20212337     DOI: 10.3855/jidc.454

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  17 in total

1.  Identification of nasal colonization with β-lactamase-producing Enterobacteriaceae in patients, health care workers and students in Madagascar.

Authors:  Volker Micheel; Benedikt Hogan; Rivo Andry Rakotoarivelo; Raphael Rakotozandrindrainy; Fetra Razafimanatsoa; Tsiriniaina Razafindrabe; Jean Philibert Rakotondrainiarivelo; Sabine Crusius; Sven Poppert; Norbert Georg Schwarz; Jürgen May; Hagen Frickmann; Ralf Matthias Hagen
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-03-26

2.  Transmission Routes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in a Neonatology Ward in Madagascar.

Authors:  Mélanie Bonneault; Volasoa Herilalaina Andrianoelina; Perlinot Herindrainy; Mamitina Alain Noah Rabenandrasana; Benoit Garin; Sebastien Breurec; Elisabeth Delarocque-Astagneau; Didier Guillemot; Zafitsara Zo Andrianirina; Jean-Marc Collard; Bich-Tram Huynh; Lulla Opatowski
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

Review 3.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

4.  Dissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo Madagascar.

Authors:  Tahiry S Andriamanantena; Elisoa Ratsima; Hanitra C Rakotonirina; Frédérique Randrianirina; Lovasoa Ramparany; Jean-François Carod; Vincent Richard; Antoine Talarmin
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-06-30       Impact factor: 3.944

5.  High prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar.

Authors:  Todisoa Andriatahina; Frédérique Randrianirina; Eliosa Ratsima Hariniana; Antoine Talarmin; Honoré Raobijaona; Yves Buisson; Vincent Richard
Journal:  BMC Infect Dis       Date:  2010-07-12       Impact factor: 3.090

6.  A multiple antibiotic and serum resistant oligotrophic strain, Klebsiella pneumoniae MB45 having novel dfrA30, is sensitive to ZnO QDs.

Authors:  Arvind Kumar; Soumynanda Chakraborti; Prachi Joshi; Pinak Chakrabarti; Ranadhir Chakraborty
Journal:  Ann Clin Microbiol Antimicrob       Date:  2011-05-19       Impact factor: 3.944

7.  Rectal carriage of extended-spectrum beta-lactamase-producing gram-negative bacilli in community settings in Madagascar.

Authors:  Perlinot Herindrainy; Frédérique Randrianirina; Rila Ratovoson; Elisoa Ratsima Hariniana; Yves Buisson; Nathalie Genel; Dominique Decré; Guillaume Arlet; Antoine Talarmin; Vincent Richard
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

8.  The epidemiological transition in Antananarivo, Madagascar: an assessment based on death registers (1900-2012).

Authors:  Bruno Masquelier; Dominique Waltisperger; Osée Ralijaona; Gilles Pison; Arsène Ravélo
Journal:  Glob Health Action       Date:  2014-05-15       Impact factor: 2.640

9.  Molecular characterization of multidrug-resistant extended-spectrum β-lactamase-producing Enterobacteriaceae isolated in Antananarivo, Madagascar.

Authors:  Hanitra C Rakotonirina; Benoît Garin; Frédérique Randrianirina; Vincent Richard; Antoine Talarmin; Guillaume Arlet
Journal:  BMC Microbiol       Date:  2013-04-17       Impact factor: 3.605

10.  Neonatal infections with multidrug-resistant ESBL-producing E. cloacae and K. pneumoniae in Neonatal Units of two different Hospitals in Antananarivo, Madagascar.

Authors:  T Naas; G Cuzon; A L Robinson; Z Andrianirina; P Imbert; E Ratsima; Z N Ranosiarisoa; P Nordmann; J Raymond
Journal:  BMC Infect Dis       Date:  2016-06-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.